Literature DB >> 1401182

Factors affecting the maintenance dose of warfarin.

A H James1, R P Britt, C L Raskino, S G Thompson.   

Abstract

AIM: To identify the possible factors determining the dose of warfarin prescribed in patients receiving anticoagulant treatment.
METHODS: The computerised records of 2305 patients maintained on the drug in seven hospitals were amalgamated and classified into one of seven diagnostic groups. The associations with the dose of warfarin prescribed were investigated by univariate and multiple regression analysis. Differences between hospitals were studied with regard to the coagulometric method and the thromboplastin preparation used.
RESULTS: The geometric mean dose of warfarin was 4.57 mg and 5% of patients were prescribed 10 mg or greater. There was a noticeable decrease in dose with increasing age, which averaged about 6 mg for patients aged 30 but 3.5 mg for those aged 80. Men required slightly more warfarin than women. Patients with heart disease or atrial fibrillation required lower doses of warfarin, while higher doses were required by patients with deep vein thrombosis. Significant differences in mean warfarin dose among the seven hospitals were evident. These differences could not be explained entirely by the use of different coagulometric methods or thromboplastins.
CONCLUSIONS: Clinicians should be aware that older patients need reduced doses of warfarin. The considerable differences in doses of warfarin among hospitals indicates that further efforts to improve uniformity are required.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401182      PMCID: PMC495149          DOI: 10.1136/jcp.45.8.704

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  3 in total

1.  Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers.

Authors:  J M Thomson; D A Taberner; L Poller
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

2.  Computer assisted management of warfarin treatment.

Authors:  R Wilson; A H James
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

3.  Dosage and control of oral anticoagulants: an international collaborative survey.

Authors:  L Poller; D A Taberner
Journal:  Br J Haematol       Date:  1982-07       Impact factor: 6.998

  3 in total
  35 in total

Review 1.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

3.  Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Authors:  Johanna H H van Geest-Daalderop; Barbara A Hutten; Augueste Sturk; Marcel M Levi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

4.  1173C>T polymorphism in VKORC1 modulates the required warfarin dose.

Authors:  K Kosaki; C Yamaghishi; R Sato; H Semejima; H Fuijita; K Tamura; K Maeyama; H Yamagishi; A Sugaya; H Dodo; Y Tanigawara; T Takahashi
Journal:  Pediatr Cardiol       Date:  2006 Nov-Dec       Impact factor: 1.655

5.  Warfarin dose requirement in patients having severe thrombosis or thrombophilia.

Authors:  Tuukka A Helin; Lotta Joutsi-Korhonen; Heidi Asmundela; Mikko Niemi; Arto Orpana; Riitta Lassila
Journal:  Br J Clin Pharmacol       Date:  2019-06-17       Impact factor: 4.335

Review 6.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 7.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

8.  Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis.

Authors:  Benjamin J Grady; Marylyn D Ritchie
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-03-01

Review 9.  Warfarin therapy: in need of improvement after all these years.

Authors:  Stephen E Kimmel
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

10.  Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.

Authors:  Mark W Linder; Stephen Looney; Jesse E Adams; Nancy Johnson; Deborah Antonino-Green; Nichole Lacefield; Bonny L Bukaveckas; Roland Valdes
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.